Compare Gilead Sciences, Inc. (GILD) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Lamb Weston Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $132.92 (market cap $163.51B), while Lamb Weston Holdings Inc trades at $46.88 (market cap $6.29B). The key difference: Gilead Sciences, Inc. is far larger — about 26× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.34%). Which is the better fit depends on your goals.
| GILD | LW | |
|---|---|---|
Market Cap | $163.51B | $6.29B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $66.57 |
52-Week Low | $108.22 | $38.48 |
Enterprise Value | $178.05B | $10.25B |
Dividend Yield | 2.49% | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Lamb Weston (LW) trades at $46.50, down 1.02% with a bullish technical outlook supported by moving averages. The company shows consistent earnings beats with Q2 2026 results pending, though net income declined to $357.2M in 2025. Valuation appears reasonable with P/E of 21.38 and P/S of 0.98. Recent news highlights strategic facility closures and upcoming Q4 earnings on July 24, 2026.
LW presents a mixed outlook with strong execution offset by margin pressure. The stock offers 6% upside to consensus target of $49.33, supported by activist involvement and cost initiatives. Key risks include legal challenges, ERP system issues, and volatile potato costs. Analyst sentiment is cautious with 35% buy ratings amid earnings uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
